- Coherus Biosciences (NASDAQ:CHRS) initiated with Buy rating and $36 (45% upside) price target by Citigroup.
- Evolent Health (NYSE:EVH) initiated with Buy rating with a $28 (17% upside) price target by Jefferies.
- GlycoMimetics (NASDAQ:GLYC) initiated with Buy rating and $16 (93% upside) price target by SunTrust Robinson Humphrey.
- Allergan plc (NYSE:AGN) initiated with Outperform rating and $327 (27% upside) price target by Credit Suisse.
- Syros Pharmaceuticals (NASDAQ:SYRS) initiated with Overweight rating and $20 (65% upside) price target by Piper Jaffray. Initiated with Outperform rating by Cowen & Company. Initiated with Outperform rating and $18 (48% upside) price target by JMP Securities and Wedbush. Initiated with Neutral rating and $10 (18% downside risk) price target by H.C. Wainwright.
- Nevro (NYSE:NVRO) initiated with Overweight rating and $98 (21% upside) price target by Piper Jaffray.
- Thermo Fisher Scientific (NYSE:TMO) initiated with Buy rating and $180 (14% upside) price target by BTIG Research.